RT Journal Article
SR Electronic
T1 <sup>110m</sup>In-DTPA-<span class="sc">d</span>-Phe<sup>1</sup>-Octreotide for Imaging of Neuroendocrine Tumors with PET
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1391
OP 1397
VO 43
IS 10
A1 Lubberink, Mark
A1 Tolmachev, Vladimir
A1 Widström, Charles
A1 Bruskin, Alexander
A1 Lundqvist, Hans
A1 Westlin, Jan-Erik
YR 2002
UL http://jnm.snmjournals.org/content/43/10/1391.abstract
AB The somatostatin analog diethylenetriaminepentaacetic acid (DTPA)-d-Phe1-octreotide labeled with 111In has been applied extensively for diagnosis of neuroendocrine tumors using SPECT or planar scintigraphy. However, the spatial resolution of planar scintigraphy and SPECT prohibits imaging of small tumors, and the quantification accuracy of both methods is limited. Methods: We developed a method to prepare the positron-emitting radiopharmaceutical 110mIn-DTPA-d-Phe1-octreotide based on a commercially available kit. Phantom studies were done to investigate and compare the performance of 110mIn PET and 111In SPECT. A clinical imaging study using 110mIn-DTPA-d-Phe1-octreotide and PET was done to investigate the application of this radiopharmaceutical. Results: An almost 3-fold better resolution and much better quantitative capabilities were found for 110mIn PET than for 111In SPECT. The clinical imaging study demonstrated the potential use of 110mIn-octreotide in PET to image tumors and quantify radioactivity uptake in humans using 110mIn-DTPA-d-Phe1-octreotide. Conclusion: PET with 110mIn-DTPA-d-Phe1-octreotide greatly improved detection of small tumors and offers a possibility of more accurate quantification of tumor uptake than can be obtained with 111In-DTPA-d-Phe1-octreotide and SPECT.